Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
"Federal debt, which is already high by historical standards, is on an unsustainable course," CBO director Phillip Swagel said in the report.Politicsread more
The president's remark followed a string of criticisms aimed at his predecessors, whom he claimed had ignored China's alleged malpractice on trade.Politicsread more
"If you look at the market over the past week, stocks don't need any help. They are roaring ahead, without the Fed doing anything," says the longtime market strategist.Marketsread more
Target CEO Brian Cornell still thinks the U.S. consumer is strong and spending. Target's latest quarterly results showed the big-box retailer is benefiting from that.Retailread more
Stocks rose on Wednesday as strong quarterly results from retailers such as Target and Lowe's lifted investor sentiment.US Marketsread more
President Trump insists the economy is healthy and says the only thing holding U.S. growth back is the Federal Reserve.Marketsread more
GOP donor John Childs has donated over $330,000 to Republican fundraising committees since being charged with soliciting prostituion.Politicsread more
Trading volumes this week are well below recent averages, and that means this comeback may be suspect.Marketsread more
These are the stocks posting the largest moves midday.Market Insiderread more
Shares of Tesla slid Wednesday on news of Walmart's lawsuit.Technologyread more
Shares of Sarepta Therapeutics fell nearly 26 percent Thursday as the Food and Drug Administration finalized new procedures for expanded access for unapproved drugs.
"Today, the FDA finalized its efforts to streamline the process used by physicians to request expanded access, often called 'compassionate use,' to investigational drugs and biologics for their patients," FDA Commissioner Robert Califf said in a statement.
This move could mean bad news for Sarepta's application for its Duchenne muscular dystrophy drug eteplirsen. The FDA was set to decide on the drug by May 26, but postponed the decision indefinitely.
Analysts were interpreting these rules from the FDA to mean there is a way for patients to access Sarepta's drug without approval, but that would limit any commercial upside for Sarepta and investors.
In a research note, analysts at Piper Jaffray said "this (FDA decision) could enable broader access to eteplirsen that the DMD community is desperate for, without forcing the agency to grant an approval at this time. ... Importantly, while sponsors can seek FDA authorization to charge for drugs in expanded access, it may only recoup direct manufacturing costs (not development or regulatory costs), limiting the sales potential."
In an email to CNBC, the FDA said its decision is not related to any specific drug or any other FDA actions. "The updates to the expanded access form and guidances has been in the works for a long time. ... We've been promising release of the final form for quite a while now and are pleased it is ready for physicians to use."
Jefferies analysts said they see a slight chance for Sarepta's eteplirsen to be approved. "Weak data could lead to significant consequences including perceived inconsistency and shift in future trial design. We continue to see a slim chance of approval given likely data-driven decision by the FDA under current laws."
Sapreta stock has shed almost half its value since the start of this year, as the FDA continued to postpone its meetings and decision on eteplirsen.
— CNBC's Meg Tirrell contributed to this report.